Current Clinical Trials

Adult Hematologic Oncology clinical trials

To inquire about malignant hematology ongoing clinical trials, please reach the clinical research team on 01-350000 Ext: 5110,  7804 or 7803

For trials involving Dr. Bazarbachi please reach Ext: 7090/1

For international clinical trials on malignant hematology or blood cancers, please check the following link: https://clinicaltrials.gov/

PI: Dr. Iman Abou Dalle

• STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

• A randomized, open-label, phase I/II open platform study evaluating safety and efficacy of novel ruxolitinib combinations in myelofibrosis patients

• Randomized dasatinib 50 vs 100 mg in chronic myeloid leukemia

Ongoing malignant hematology clinical research projects:

Malignant hematology & stem cell transplant research

PI: Dr. Jean el Cheikh:

• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

PI: Dr. Ali Bazarbachi:

• A phase 3, multicenter, open-label, randomized study of oral ABL001 versus bosutinib in patients with chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors (CABL001A2301)

• Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia (LPI-JOR-LEB-KSA-TUN-2017-01)

• A randomized, double-blind, placebo-controlled phase III multi-center study of Azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)”. IRB ID: CMBG453B12301/BIO-2020-0171.